Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed neutropenia with ticlopidine

D K Farver1, L A Hansen

  • 1Department of Clinical Pharmacy, South Dakota State University College of Pharmacy, Yankton.

The Annals of Pharmacotherapy
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in demographics and clinical outcomes in older, middle-aged, and younger adults with low back pain receiving chiropractic care.

Chiropractic & manual therapies·2025
Same author

A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.

Oncogene·2011
Same author

In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution.

Neurology·2007
Same author

The shifting patterns of HIV encephalitis neuropathology.

Neurotoxicity research·2005
Same author

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Neurology·2005
Same author

Anosmia is very common in the Lewy body variant of Alzheimer's disease.

Journal of neurology, neurosurgery, and psychiatry·2005
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
See all related articles

Ticlopidine can cause neutropenia, a serious condition, even weeks after stopping the medication. This case highlights the need for extended monitoring beyond the standard 14 days for patients on ticlopidine.

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Medicine

Background:

  • Ticlopidine is an antiplatelet medication used to prevent thrombotic events.
  • Drug-induced neutropenia is a potentially severe adverse effect associated with various medications.
  • Previous reports have documented ticlopidine-induced neutropenia during treatment.

Observation:

  • A 68-year-old woman developed neutropenia and pneumonia 18 days after discontinuing ticlopidine.
  • The patient initially received ticlopidine for a transient ischemic attack.
  • The drug was discontinued after 10 days due to a rash.

Findings:

  • This case presents ticlopidine-induced neutropenia occurring significantly after drug cessation.
  • The delayed onset of neutropenia suggests a prolonged or delayed hypersensitivity reaction.

Related Experiment Videos

  • Complete blood cell count monitoring is crucial during ticlopidine therapy.

    • Implications:

    • The findings suggest that current monitoring guidelines for ticlopidine may be insufficient.
    • Extended monitoring for neutropenia after ticlopidine discontinuation may be warranted.
    • Physicians should maintain a high index of suspicion for delayed drug-induced neutropenia.